Located near Tampa, 30,000 sq. ft. facility in Manatee County’s City of Palmetto will house state-of-the-art manufacturing operation and surgeon training center for pioneer of bio-integrative, metal-free fixation implants
TAMPA, Fla.–(BUSINESS WIRE)–#medicaldevice—OSSIO Inc., a fast-growing medical technology company focused on evolving orthopedic surgery with bio-integrative, metal-free fixation implants, has selected Florida — specifically, the City of Palmetto in Manatee County, near Tampa — as the location of its new U.S headquarters, a move that is expected to create about 100 new jobs over the next five years.
“Florida welcomes OSSIO as part of our effort to make the Sunshine State a global life sciences hub, with multiple centers of life sciences investment, research and development, and public-private collaboration,” said Florida Secretary of Commerce, J. Alex Kelly. “Aligned with the manufacturing vision of Gov. Ron DeSantis, Florida now ranks second for medical device and pharmaceutical manufacturing, and Florida supports these industries with the nation’s fifth largest investment in biotech research and development activities. The addition of OSSIO to our health technology sector will directly elevate Florida’s life sciences job and innovation outcomes.”
OSSIO recently started converting 30,000 square feet of leased space in Palmetto into a state-of-the-art manufacturing operation and surgeon training center.
“Florida fosters a culture of innovation in health care and life sciences that OSSIO intends to strengthen by locating our U.S. headquarters here,” OSSIO CEO Brian Verrier said. “The Tampa region in particular offers medical technology companies like ours an attractive combination of technical talent and economic incentives to support sustainable growth.”
Recruiting set to start
OSSIO plans to begin recruiting for manufacturing technicians, clinical trainers and support staff in the fall and to start producing OSSIOfiber® implants at the new site in the spring.
“We are thrilled to have OSSIO join the Palmetto community,” the city’s mayor, Dan West, said. “Their presence reflects the ongoing growth and innovation in our city, and we look forward to supporting their success. Palmetto is a city that values strong partnerships, and OSSIO is a wonderful addition to our local business family.”
OSSIO HQ also promises to benefit the Tampa Medical & Research District, which encompasses several organizations associated with Tampa General Hospital and the University of South Florida.
“As the Tampa Medical & Research District develops,” explained Tampa General Hospital SVP Jennifer Crabtree, the organization’s newly appointed president, “I envision involving innovative life sciences companies with nearby operations like OSSIO in our work, which centers on making Florida’s southwest coast a center of excellence for health care innovation.”
In addition, OSSIO recently joined BioFlorida, the state’s trade association for the health care and medical technology industry.
“OSSIO represents exactly the kind of innovative company that strengthens Florida’s life sciences ecosystem,” said BioFlorida President and CEO Mark Glickman. “Their orthopedic implant technology is a true game-changer by offering patients a metal-free, more natural way to heal after surgery. We are proud to welcome OSSIO to BioFlorida and look forward to supporting the company’s growth and impact in advancing medical technology.”
About OSSIOfiber implants
Based on Intelligent Bone Regeneration Technology, OSSIOfiber implants combine unparalleled mechanical strength and natural healing in a bio-integrative, metal-free design. Their proprietary polymeric mineral fiber matrix enables rapid bone in-growth, regeneration and replacement — a new way for orthopedic surgeons to restore their patients’ stability and mobility while leaving nothing permanent behind.
OSSIOfiber implants represent the first credible alternative to metal, absorbable and allograft fixation devices. The most significant advance in orthopedic fixation technology in more than 100 years, this novel medical technology has the potential to address an increasingly wide array of surgical applications due to the proprietary “know-how” to manufacture limitless implant platforms. Looking ahead, the company intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.
Notably for U.S. healthcare providers and payors, OSSIOfiber implants utilize existing reimbursement codes and surgical techniques. Their uptake continues to grow because of strong patient and surgeon preference to avoid the concerns and complications of metal fixation implants. Through September 2025, more than 60,000 OSSIOfiber implants have been used to treat orthopedic patients in the U.S.
About OSSIO Inc.
OSSIO is an orthopedics company committed to transforming the surgical experience for patients, physicians, providers and payors. The company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. Founded in 2014, the company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development in Caesarea, Israel, and commercial operations from Woburn, Mass. For more information about the company and OSSIOfiber implants, visit www.ossio.io.
Disclaimer: Forward-looking statements in this news release are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
Contacts
Joe McGrath
Scope Strategic Communications
[email protected]
+1-612-819-6421
